Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0049 crossover study in allergic conjunctivitis
jRCT2031260374Phase 3Recruiting
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Aug 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of mapracorat in allergic conjunctivitis (AC) (3 arms), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Subjective ocular symptom score. Started Aug 2026; status: recruiting.
02
Drugs
mapracorat
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on jRCT2031260374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260374.